

ASX ANNOUNCEMENT

CELLMID RECEIVES CHINESE IMPORT PERMITS

- **Chinese import permits have been received for Jo-Ju® and Lexilis®**
 - **Orders to existing channels can now be shipped**
 - **Negotiations for sales in new channels can resume**

SYDNEY, Tuesday, 1 August 2017: Cellmid Limited (ASX:CDY) is pleased to advise that import permits to China have been renewed and are now in place. As noted in the commentary to the Appendix 4C released on 28 July 2017, orders to China could not be shipped due to the delay in receiving these renewals. This has impacted overall sales for the 2017 financial year.

Import permits for special purpose cosmetics in China carry fixed terms, and the Jo-Ju® and Lexilis® lotions' permits expired in August 2016. Documentation for the renewals was submitted well before the expiry. The delay was the result of increasingly strict guidelines by Chinese authorities for the granting of import permits, particularly those with therapeutic claims.

As a result of receiving the import permits:

1. Orders that have been put on hold can now be shipped; and
2. Negotiations with new channels for the sale of products in China which had been halted due to the substantial delay will now resume.

With the renewed permits Cellmid will continue its multi-platform marketing effort of Jo-Ju® and Lexilis® lotions in China and build on the substantial success already achieved in Japan.

"We are extremely pleased to have successfully renewed these import permits, which will allow us to fulfil orders to China" said Koichiro Koike, Managing Director of Cellmid's wholly owned subsidiary, Advangen Inc. "These permits for special purpose cosmetics are increasingly difficult to secure and it is to the credit of our dedicated team that we have been able to do so and access the substantial Chinese consumer market" he added.

The renewed permits are for the period of four years to July 2021.

End

Contact: Maria Halasz, CEO

T +612 9221 6830



@mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with lead programs in multiple disease indications. The Company, through its wholly owned subsidiaries, Lyramid, Kinera and Advangen, develops and markets innovative novel therapies and diagnostic tests for fibrotic diseases, cancer, ischemic diseases of the heart and hair loss. Cellmid holds the largest and most comprehensive portfolio of intellectual property relating to the novel targets midkine (MK) and FGF5 globally. Intellectual property pertaining to midkine is being exploited through wholly owned subsidiaries Lyramid and Kinera. Advangen, Cellmid's consumer health business, sells its FGF5 inhibitor hair growth products in Australia, Japan and the USA and currently expanding distribution in other territories. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au.

Advangen Limited and hair growth products

Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of anti-aging hair care products. Advangen has a range of FGF5 inhibitor hair growth products which are sold in Australia, Japan, China and Taiwan. Concurrently, Advangen has been developing midkine, a growth factor, in hair loss models utilising its anti-apoptotic and growth promoting effects. Advangen has a rich portfolio of hair growth and anti-aging hair care assets which include formulations of products on market, trademarks, patents and patent applications, proprietary assays and manufacturing processes.

Investment in life sciences companies

Several inherent risks associated with the research, development and commercialisation of pharmaceutical products. Investment in companies specialising in these activities carry specific risks which are different to those associated with trading and manufacturing businesses. As such, these companies should be regarded as highly speculative. Cellmid recommends that investors seek professional advice before making an investment in its shares.